# AB-3028

Source: https://onco.cc/drugs/ab-3028/  
OnCo record `ab-3028` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AB-3028 is an experimental autologous programmable circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer.

## Summary

AB-3028 is an autologous programmable circuit T cell therapy from Arsenal Biosciences. An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07285694 active, not recruiting; started 9 January 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: AB-3028
- Modality: Autologous programmable circuit T cell therapy
- Mechanism: An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets.

## Sources

- Arsenal Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07285694
- ClinicalTrials.gov: trials of AB-3028: https://clinicaltrials.gov/search?intr=AB-3028

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/)
- trials: [AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)](https://onco.cc/trials/nct07285694/)

---
JSON: https://onco.cc/api/v1/entities/ab-3028.json